[Added entry for Telaprevir in Asia, although this is technically a monetization of a prior agreement This list does not purport to be complete. Items are listed in descending order of up-front amount.]
*For rights in Europe, South America, Australia, and the Middle East. †For rights in Japan/Asia; monetization of amended 2004 agreement. ‡Includes $75M NVS paid for rights to NM283 and telbivudine in 2003.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.